Anne-Sophie Casagrande

This inventor holds 5 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: Allergan, Inc., Exonhit Therapeutics, Sa, Diaxonhit. Active years: 2014-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Anne-Sophie Casagrande. Retrieved from https://idiyas.com/inventor/anne-sophie-casagrande

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5 (Patent Applications = 2)

% Patents Active = 100.0

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 4)

Average Co-Inventor Count = 7.8

ph-index = 1

Forward Citations = 4(Granted Patents)

Location History:

Draveil, FR (2014 - 2016)
Draveli, FR (2015 - 2018)

Company Filing History:

Exonhit Therapeutics, Sa

where one patent can have more than one assignee

Years Active: 2014-2018

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9902710 - Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) (2018-02-27),

2. 9670181 - Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) (2017-06-06),

3. 9446044 - DYRK1 inhibitors and uses thereof (2016-09-20),

4. 9200016 - Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) (2015-12-01),

5. 8772316 - Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE10A) (2014-07-08),

Title: The Innovative Contributions of Anne-Sophie Casagrande

Introduction

Anne-Sophie Casagrande is a prominent inventor based in Draveli, France. She has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target phosphodiesterase 10 (PDE 10A). With a total of five patents to her name, her work has the potential to impact the treatment of various central nervous system diseases.

Latest Patents

Among her latest patents are the "Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)." This invention relates to compounds that are useful in treating conditions such as psychosis, obesity, type II diabetes, metabolic syndrome, glucose intolerance, pain, and ophthalmic diseases. Another notable patent is the "Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)," which shares similar applications and benefits.

Career Highlights

Throughout her career, Anne-Sophie has worked with notable companies such as Allergan, Inc. and Exonhit Therapeutics. Her experience in these organizations has allowed her to refine her skills and contribute to groundbreaking research in the pharmaceutical industry.

Collaborations

Anne-Sophie has collaborated with esteemed colleagues, including Bertrand Leblond and Thierry Taverne. These partnerships have fostered an environment of innovation and have led to the successful development of her patented compounds.

Conclusion

Anne-Sophie Casagrande's work exemplifies the impact of innovative thinking in the pharmaceutical field. Her contributions through her patents are paving the way for new treatments for various diseases, showcasing her dedication to improving healthcare.

Profile summary based on public USPTO records.